Otherwise, IL‐12 has re‐emerged via control circuits that confine its expression to the tumor (e.g., hypoxia‐responsive or activation‐inducible knock‐ins), as well as mesothelin/MUC16 programs exploring regional delivery in early‐phase trials; together these data support context‐restricted IL‐12 as a potent, clinically tractable amplifier of antigen‐directed killing. Here, MSLN is linked to neoplasm.